A Study of DM002 in Patients With Advanced Solid Tumors

NCT06751329 | Recruiting Phase 1 FDA Drug

• 1 other identifier: DM002001
• Study Type: interventional
• Target: 160
• Locations: 2 countries
• Sites: 5

Brief Summary

The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling new participants at a higher dose of study drug. There will be up to six or more dose levels of study drug tested (called cohorts). Which dose you receive will depend on how many participants have taken part in the study before you. The purpose of Part 1 of the study is to evaluate the safety of the study drug at different dose levels, to understand what your body does to the study drug, and to find the best dose of study drug in people who have advanced solid tumor cancers. In Part 2, participants will receive the best dose level that was determined in Part 1 of the study. The purpose of Part 2 of the study is to evaluate the safety of the study drug at the dose level determined in Part 1, to understand what your body does to the study drug, and to see how your cancer responds to the study drug. Participants will: Participants will have 17 or more visits to the study centre. This study has a screening phase of up to 28 days , and a treatment phase with cycles of 21 days each. Participants will also have an End of Treatment (EOT) visit 21 days after the final study drug treatment, and a Follow-up visit 30 days after the EOT visit . Participants will be contacted by telephone every 3 months after the Follow-up visit to check on the wellbeing and record any new anticancer therapy they may have started.

Conditions

Ovarian Neoplasms; Prostatic Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Solid Carcinoma

Outcome Measures

Primary Outcomes (2)

• Dose-limiting Toxicities (DLTs) of DM002

  Incidence of DLTs of DM002 will be determined. A dose-limiting toxicity (DLT) is defined as grade 3 neurological toxicities (e.g. chemical meningitis) or other grade 4 toxicities.

  12 months

• Maximum tolerated dose (MTD) for DM002

  The MTD of DM002 will be determined. The MTD is defined as the dose where 0/3 or 1/6 patients experienced a DLT with at least two patients encountering DLT at the higher dose.

  12 months

Secondary Outcomes (5)

• Area Under the Curve（AUC，ng·h/mL）

  12 months

• Maximum (peak) plasma concentration (Cmax, ng/mL)

  12 months

• Time to maximum (peak) concentration (Tmax, h)

  12 months

• Trough concentration (Ctrough, ng/mL)

  12 months

• Objective response rate (ORR)

  12 months

Study Arms (6)

Dose Level 1

EXPERIMENTAL

1.0 mg/kg

Drug: DM002

Dose Level 2

EXPERIMENTAL

≤2.0 mg/kg

Drug: DM002

Dose Level 3

EXPERIMENTAL

≤3.0 mg/kg,

Drug: DM002

Dose Level 4

EXPERIMENTAL

≤4.5 mg/kg

Drug: DM002

Dose Level 5

EXPERIMENTAL

≤6.0 mg/kg

Drug: DM002

Dose Level 6

EXPERIMENTAL

≤7.5 mg/kg

Drug: DM002

Interventions

DM002 DRUG

An IV infusion of DM002 will be administrated approximately 30-60 min on D1 once Q3W

Dose Level 1; Dose Level 2; Dose Level 3; Dose Level 4; Dose Level 5; Dose Level 6

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must have the ability to understand and willingness to sign a written informed consent document.
• Subjects must be ≥18 years of age at the time of signing the informed consent form.
• Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
• Has a life expectancy of ≥3 months.
• Participants must meet the following laboratory values within 7 days prior to first dose of study drug:
• Note: Transfusion (red blood cell or platelet) or granulocyte-colony stimulating factor (G-CSF) administration is not allowed within 2 weeks prior to laboratory assessments at Screening.
• Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L;
• Platelet count ≥100 × 10⁹/L;
• Hemoglobin ≥9 g/dL;
• Calculated creatinine clearance (CrCL) \>60 mL/min (Cockroft-Gault Equation);
• Total bilirubin ≤ 1.5 x ULN;
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0 × upper limit of normal (ULN), if liver metastases are present, ≤5 × ULN;
• International normalized ratio (INR)\<2.0, and prothrombin time and either partial thromboplastin time (PTT) or activated PTT (aPTT) ≤1.5 × ULN, except for participants receiving anti-vitamin K derivative anticoagulant therapy who must have prothrombin time/INR within therapeutic range as deemed appropriate by the Investigator.
• Has measurable disease based on RECIST version 1.1.
• Participants are required to provide tumor tissue specimens obtained within the previous 3 years for the measurement of MUC1 and/or HER3 and other biomarkers. For those subjects who are unable to provide tissue samples will be encouraged (but not mandatory) to undergo biopsy if the risk is manageable. If the biopsy is not possible, it should inform the sponsor for enrolment.

You may not qualify if:

• Subjects have another active invasive malignancy within 5 years, with the following exceptions and notes:
• History of noninvasive malignancy, such as cervical cancer in situ, in situ melanoma, or ductal carcinoma in situ of the breast that is in complete remission 5 years after treatment with curative intent is allowed.
• Malignancies with a negligible risk of metastasis or death (such as adequately treated basal or squamous cell skin cancer and localized prostate cancer).
• Current or history of a hematologic malignancy.
• Anticancer therapy (chemotherapy, immunotherapy, hormonal therapy, targeted therapy, biologic therapy, or other anti-cancer therapies, except for hormones for hypothyroidism or estrogen replacement therapy, anti-estrogen analogs, agonists required to suppress serum testosterone levels) within 28 days or 5 half-lives, whichever is shorter, prior to the first study dose. Radiotherapy with a wide field of radiation within 28 days, or radiotherapy with a limited field of radiation for palliation within 14 days of the first study dose. Major surgery, other than diagnostic surgery, within 4 weeks of the first study dose.
• Primary central nervous system (CNS) malignancies or CNS metastases. Individuals with brain metastases can be enrolled only if treated, nonprogressive brain metastases and off high-dose steroids (\>20 mg prednisone or equivalent) for at least 4 weeks.
• History of known allergies to ADC, or prior discontinuation of an ADC due to treatment-related toxicities. Has received prior treatment with ADCs that include topoisomerase I (Topo I) payload, and treatment history with any investigational drug within 4 weeks before enrolment in the study.
• Has an uncontrolled infection requiring IV injection of antibiotics, antivirals, or antifungals.
• Has a pre-existing clinically significant lung diseases (e.g., interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or pre-existing ocular disorders.
• Clinically uncontrolled intercurrent illness, including but not limited to an ongoing active infection, active coagulopathy, uncontrolled cardiovascular disease, uncontrolled immune disease, uncontrolled diabetes, uncontrolled pleural and peritoneal effusion, psychiatric illness that would limit compliance with the study requirements and other serious medical illnesses requiring systemic therapies.
• Mean resting corrected QT interval corrected by Fridericia's formula (QTcF) \>470 msec obtained from triplicate 12-lead ECGs at baseline; using concomitant medications that would prolong the QT interval.
• Left ventricular ejection fraction \<50% by either an echocardiogram (ECHO) or a multi-gated acquisition scan within 28 days before first dose of the study drug.
• Known active hepatitis B (HBV) or hepatitis C (HCV) infection. Chronic carriers of HBV infection (HBsAg-positive, undetectable HBV DNA or HBV DNA ≤2500 copies/ml or 500 IU/ml) receive prophylactic treatment during the study can be enrolled. Participants with a history of HCV infection have completed curative antiviral treatment and HCV viral load below the limit of quantification and HCV antibody positive but HCV ribonucleic acid (RNA) negative due to prior treatment or natural resolution should be eligible.
• Known human immunodeficiency virus (HIV) infection which is not well controlled. Participants should be tested for HIV prior to enrollment if required by local regulations or institutional review board (IRB)/ethics committee. All the following criteria are required to define an HIV infection (positive HIV1/2 antibodies test) that is well controlled: HIV viral load \<400 copies/mL, CD4+ T- cell counts ≥350 cells/μL, no history of acquired immunodeficiency syndrome-defining opportunistic infection within the past 12 months, and stable viral load for at least 4 weeks on same anti-HIV retroviral medications.
• Subjects who are from endemic areas (refer to WHO high tuberculosis burden country list, China is endemic area) will be specifically screened for tuberculosis with any available test. Subjects with active tuberculosis are excluded. Subjects who have received bacille Calmette-Guerin vaccination may have a false positive result of purified-protein derivative (PPD) test. These subjects are eligible if they have a negative result of interferon gamma release assay (IGRA).

Sponsors & Collaborators

• Xadcera Biopharmaceutical (Suzhou) Co., Ltd.: lead

Study Sites (5)

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73190, United States

RECRUITING

The University of Texas, MD Anderson Cancer Center

Houston, Texas, 77030, United States

RECRUITING

Scientia Clinical Research

Randwick, New South Wales, Australia

RECRUITING

Cancer Care Wollongong

Wollongong, New South Wales, 2500, Australia

RECRUITING

Southern Oncology Clinical Research Unit

Adelaide, South Australia, Australia

RECRUITING

MeSH Terms

Conditions

Ovarian Neoplasms; Prostatic Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders; Genital Neoplasms, Male; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Uterine Neoplasms; Uterine Diseases; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 11, 2024
• First Posted: December 27, 2024
• Study Start: February 17, 2025
• Primary Completion (Estimated): October 8, 2027
• Study Completion (Estimated): April 18, 2028
• Last Updated: January 15, 2026

Record last verified: 2026-01

Locations

AU (3); US (2)